Current Areas of Disease Research :

Type 2 Diabetes & Obesity
Chronic Kidney Disease
Obesity
Hypothyroidism

___________________________________________________________________________________________________________________________________________________________________________________________________________________

Active – Recruiting:

BaxDuo Arctic / D6972C00003

The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin alone.

Condition: Chorionic Kidney Disease with Proteinuria
Status: Active – Recruiting
Sponsor: AstraZeneca
Type of Study: A Phase III, Randomised, Double-Blind, Active-controlled Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants With CKD and High Blood Pressure
Study Length: 24-months
Target Age/Sex:18 Years to 130 Years (Adult, Older Adult)
Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT04419779
To fill out a pre-screening survey please visit: https://www.woendo.com/research-screening/

Avanti / M21-341

A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

Condition: Hypothyroidism
Status: Active – Recruiting
Sponsor: AbbVie
Type of Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism
Study Length: 81 Weeks
Target Age/Sex: 18 Years to 75 Years (Adult, Older Adult)
Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT06345339
To fill out a pre-screening survey please visit: https://www.woendo.com/research-screening/

ReCET / 898

Condition: Type II Diabetes
Status: Active – Recruiting
Sponsor: Endogenex
Type of Study: A Multicenter, Randomized, Double-blind, Sham-controlled study for Assessing the Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals with Type II Diabetes.
Study Length: 52 Weeks
Target Age/Sex: 18 Years to 70 Years (Adult, Older Adult)
Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
Check Procedure Video: https://www.endogenex.com/recet/
To check eligibility criteria please visit: https://clinicaltrials.gov/study/NCT06267391
To fill out a pre-screening survey please visit: https://www.woendo.com/research-screening/

Active – Closed Enrollment

ACHIEVE-4 / J2A-MC-GZGS

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk.

Condition: Type 2 Diabetes and Obesity
Status: Active, Closed Enrollment.
Sponsor: Eli Lilly
Type of Study: A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk.
Study Length: 104 weeks
Target Age/Sex: 18 Years and older, Male and Female
Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT05803421
To fill out a pre-screening survey please visit: https://www.woendo.com/research-screening/

ACHIEVE-3 / J2A-MC-GZGU

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin.

Condition: Type 2 Diabetes and Obesity
Status: Active, Closed Enrollment.
Sponsor: Eli Lilly
Type of Study: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-3)
Study Length: 52 Weeks
Target Age/Sex: 18 Years and older (Adult, Older Adult)
Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT06045221
To fill out a pre-screenig survey please visit: https://www.woendo.com/research-screening/

ACHIEVE-1 / J2A-MC-GZGT

Effect of LY3502970 Compared with Placebo in Participants with Type 2 Diabetes Inadequately Controlled with Diet and Exercise Alone

Condition: Type 2 Diabetes and Obesity
Status: Active, Closed Enrollment.
Sponsor: Eli Lilly
Type of Study: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 compared with Placebo in Adult Participants with Type 2 Diabetes and inadequate Glycemic Control with Diet and Exercise Alone.
Study Length: 42 weeks
Target Age/Sex: 18 Years and older, Male and Female
Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT03736785
To fill out a pre-screenig survey please visit: https://www.woendo.com/research-screening/

SYNCHRONIZE™-2 / 1404-0041

A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight.

Condition: Type 2 Diabetes and Obesity
Status: Active, Closed Enrollment.
Sponsor: Boehringer Ingelheim
Type of Study: A Phase 3, randomized, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus.
Study Length: 76weeks
Target Age/Sex: 18 Years and older, Male and Female
Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT06066528
To fill out a pre-screenig survey please visit: https://www.woendo.com/research-screening/

REIMAGINE 2 / NN9388-4896

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (REIMAGINE 2)

Condition: Type 2 Diabetes and Obesity
Status: Active, Closed Enrollment.
Sponsor: Novo Nordisk
Type of Study: a Phase 3 study to measure the efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor
Study Length: 68 Weeks
Target Age/Sex: 18 Years and older (Adult, Older Adult)
Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT06065540
To fill out a pre-screenig survey please visit: https://www.woendo.com/research-screening/

REIMAGINE 4 / NN9388-4894

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Condition: Type 2 Diabetes and Obesity
Status: Active, Closed Enrollment.
Sponsor: Novo Nordisk
Type of Study: a Phase 3 study to measure the efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. Once Weekly Versus Tirzepatide 15 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor
Study Length: 68 Weeks
Target Age/Sex: 18 Years and older (Adult, Older Adult)
Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT06221969
To fill out a pre-screenig survey please visit: https://www.woendo.com/research-screening/

Revitalize 1 / C-00044

Evaluation of the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes on Insulin Therapy

Condition: Type 2 Diabetes and Obesity
Status: Active, Closed Enrollment.
Sponsor: Fractyl
Type of Study: A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes on Insulin Therapy
Study Length: 24 Weeks
Target Age/Sex: 21 Years to 70 Years (Adult, Older Adult)
Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT04419779
To fill out a pre-screenig survey please visit: https://www.woendo.com/research-screening/

Confidence / 21839

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes (CONFIDENCE)

Condition: Chorionic Kidney Disease with Proteinuria
Status: Active, Closed Enrollment.
Sponsor: Bayer
Type of Study: A Parallel-group Treatment, Phase 2, Double-blind, Three-arm Study to Assess Efficacy and Safety of Finerenone Plus Empagliflozin Compared With Either Finerenone or Empagliflozin Alone in Participants With Chronic Kidney Disease and Type 2 Diabetes.
Study Length: 30 Weeks
Target Age/Sex: 18 Years and older (Adult, Older Adult)
Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
To check eligibility criteria please visit: https://classic.clinicaltrials.gov/ct2/show/NCT05254002
To fill out a pre-screenig survey please visit: https://www.woendo.com/research-screening/

SYNCHRONIZE™-1 / 1404-0038

Efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes.

Condition: Obesity
Status: Active, Closed Enrollment.
Sponsor: Boehringer Ingelheim
Type of Study: A Phase III, randomized, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes.
Study Length: 76 weeks
Target Age/Sex: 18 Years and older, Male and Female
Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
Link: https://classic.clinicaltrials.gov/ct2/show/NCT06066515

STABILIZE-CKD – D9488C0001

Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants with CKD and Hyperkalemia or at Risk of Hyperkalemia

Condition: Chorionic Kidney Disease with Proteinuria
Status: Closed – Closed Enrollment
Sponsor: AstraZeneca
Type of Study: A Phase 3, International, Randomized, Double-Blind.
Study Title: Placebo Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Patients with CKD and Hyperkalemia or at Risk of Hyperkalemia
Study Length: 28 months
Target Age/Sex: Over 18 years, Male and Female
Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
Link: https://clinicaltrials.gov/ct2/show/NCT05056727

QWINT-3 – I8H-MC-BDCU

The QWINT-3 Study is testing an investigational basal insulin taken once weekly compared with basal insulin that is taken daily.

Condition: Type 2 Diabetes
Sponsor: Eli Lilly
Status: Closed – Closed Enrollment.
Type of Study: A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
Study Length: 86 weeks
Target Age/Sex: 18 Years and older, Male and Female
Benefits: Qualified trial participants will receive study medication, study-related supplies, study-related lab work, and study-related exams at no cost.
Link: https://classic.clinicaltrials.gov/ct2/show/NCT03736785

Completed Trials:

1.NCT Number: NCT00698230. Study Name: . Sponsor: Incyte Corporation. Role: Sub- Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2008. Completed Date: 2009.

2.NCT Number: NCT00707993. Study Name: . Sponsor: Takeda. Role: Sub- Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2008. Completed Date: 2010.

3.NCT Number: NCT00751842. Study Name: DIAPREVENT. Sponsor: Diamyd Therapeutics AB. Role: Sub- Investigator. Condition I: Type I Diabetes Mellitus. Start date: 2012. Completed Date: 2012.

4.NCT Number: NCT01989754. Study Name: CANVAS. Sponsor: Janssen Research & Development, LLC. Role: Sub- Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2014. Completed Date: 2017.

5.NCT Number: NCT00789737. Study Name: . Sponsor: Daiichi Sankyo, Inc. Role: Sub- Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2009. Completed Date: 2011.

6.NCT Number: NCT01018173. Study Name: . Sponsor: Roche. Role: Sub- Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2010. Completed Date: 2011.

7.NCT Number: NCT01499082. Study Name: Edition I. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2016. Completed Date: 2018.

8.NCT Number: NCT02855684. Study Name: Edition AP. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2016. Completed Date: 2018.

9.NCT Number: NCT01995734. Study Name: ACCESS. Sponsor: Novartis Pharmaceuticals. Role: Principal Investigator. Condition I: Acromegaly. Start date: 2013. Completed Date: 2015.

10.NCT Number: NCT02058147. Study Name: . Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2014. Completed Date: 2015.

11.NCT Number: NCT02058147. Study Name: . Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2014. Completed Date: 2015.

12.NCT Number: NCT02320721. Study Name: SENIOR. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2015. Completed Date: 2016.

13.NCT Number: NCT02294474. Study Name: SORELLA2. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2015. Completed Date: 2016.

14.NCT Number: NCT02967224. Study Name: (Reach-Control). Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2015. Completed Date: 2017.

15.NCT Number: NCT02642159. Study Name: ODYSSEY DM-Dyslipidemia. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2016. Completed Date: 2017.

16.NCT Number: NCT02738151. Study Name: BRIGHT. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2016. Completed Date: 2017.

17.NCT Number: NCT02688933. Study Name: . Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2016. Completed Date: 2017.

18.NCT Number: NCT03211858. Study Name: GEMELLI1. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type I Diabetes Mellitus. Start date: 2019. Completed Date: 2019.

19.NCT Number: NCT03066830. Study Name: SOTA-SU. Sponsor: Lexicon Pharmaceuticals. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2019.

20.NCT Number: NCT03242018. Study Name: SOTA-CKD4. Sponsor: Lexicon Pharmaceuticals. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2019.

21.NCT Number: NCT03242252. Study Name: SOTA-CKD3. Sponsor: Lexicon Pharmaceuticals. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2019.

22.NCT Number: NCT03332771. Study Name: SOTA-GLIM. Sponsor: Lexicon Pharmaceuticals. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2019.

23.NCT Number: NCT03449199. Study Name: . Sponsor: Teijin America, Inc. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2018. Completed Date: 2019.

24.NCT Number: NCT03518034. Study Name: TRAVERSE. Sponsor: AbbVie. Role: Principal Investigator. Condition I: Hypogonadism. Start date: 2018. Completed Date: 2023.

25.NCT Number: NCT03351478. Study Name: SOTA-EMPA. Sponsor: Lexicon Pharmaceuticals. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2019.

26.NCT Number: NCT02092467. Study Name: . Sponsor: Pfizer. Role: Principal Investigator. Condition I: RHEUMATOID ARTHRITIS. Start date: 2014. Completed Date: 2020.

27.NCT Number: NCT03285594. Study Name: SOTA-INS. Sponsor: Lexicon Pharmaceuticals/ Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2019.

28.NCT Number: NCT03767543. Study Name: DIVERSITY. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2019. Completed Date: 2020.

29.NCT Number: NCT03874715. Study Name: GEMELLI X. Sponsor: Sanofi. Role: Principal Investigator. Condition I: Type I Diabetes Mellitus. Start date: 2019. Completed Date: 2020.

30.NCT Number: NCT03895203. Study Name: BE OPTIMAL. Sponsor: UCB Biopharma SRL. Role: Principal Investigator. Condition I: Psoriatic Arthritis. Start date: 2019. Completed Date: 2022.

31.NCT Number: NCT03071692. Study Name: PROMINENT. Sponsor: Kowa Research Institute, Inc. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2017. Completed Date: 2022.

32.NCT Number: NCT03990363. Study Name: SAPPHIRE. Sponsor: AstraZeneca. Role: Principal Investigator. Condition I: Chronic Kidney Disease. Start date: 2019. Completed Date: 2022.

33.NCT Number: NCT04064411. Study Name: The wearABLe Study. Sponsor: Radius Health, Inc. Role: Principal Investigator. Condition I: Osteoporosis. Start date: 2019. Completed Date: 2021.

34.NCT Number: NCT04274894. Study Name: . Sponsor: AbbVie. Role: Principal Investigator. Condition I: Hypogonadism. Start date: 2020. Completed Date: 2021.

35.NCT Number: NCT04854512. Study Name: DREAM-T2D. Sponsor: Anji Pharma. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2018. Completed Date: 2023.

36.NCT Number: NCT04419467. Study Name: . Sponsor: CSL Behring. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2020. Completed Date: 2022.

37.NCT Number: NCT04657003. Study Name: SURMOUNT-2. Sponsor: Eli Lilly and Company. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2021. Completed Date: 2023.

NCT Number: NCT05182840. Study Name: MANOUVER. Sponsor: Boehringer Ingelheim. Role: Principal Investigator. Condition I: Type 2 Diabetes Mellitus. Start date: 2022. Completed Date:

Clinical Trials